APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology

Talyansky, Seth; Le Guen, Yann; Kasireddy, Nandita; Belloy, Michael E.; Greicius, Michael D.

doi:10.1186/s40478-023-01626-6

Acta Neuropathologica Communications

Table 3 Number of individuals in pathology categories across analyses

From: APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology

	Current sample	Initial sample × Tsuang et al. [51] criteria	Initial sample × Kaivola et al. [27] criteria	Tsuang et al. [51]	Kaivola et al. [27]	Chia et al. [13]
AD⁺LB⁺	1,072	916	695	224	66/341^a	?
AD⁺LB^–	2,492	2,492	3,493	244	0	0
AD^–LB⁺	158	316	158	91	88	?
AD^–LB^–	1,263	1,358	908	269	2,928	4,027
LB^+b	N/A	N/A	N/A	N/A	N/A	2,591
LB^–b	N/A	N/A	N/A	N/A	N/A	N/A

	Beecham et al. [2]	Bras et al. [10]	Chung et al. [14]	Dickson et al. [18]	Guerreiro et al. [24]	Robinson et al. [45]	Sabir et al. [47]
AD⁺LB⁺	?	?	215	10/27/115/19/111/209^a	?	130/96^a,c	?
AD⁺LB^–	?	0	316	0	0	16/60^a	0
AD^–LB⁺	?	?	0	46/80/33^a	?	10/12/22^a	?
AD^–LB^–	?	2,624	0	660	3,791	0	591
LB^{+ b}	2,391	667	N/A	N/A	1,216	N/A	525
LB^{– b}	1,135	N/A	N/A	N/A	N/A	N/A	N/A

Not all classifications were necessarily pathologically confirmed (Additional file 1: Table S1). First column: our study cohort. Next two columns: our preliminary cohort (before the removal of individuals not classified by our criteria) classified using literature criteria (Fig. 1a–b) [27, 51]. Remaining columns: category sizes in literature cohorts [2, 10, 13, 14, 18, 24, 27, 45, 47, 51]. For Beecham et al., Robinson et al., and Sabir et al., only analyses of APOE-ε4-associated risk for LB pathology or dementia are considered [2, 45, 47]. For Guerreiro et al., we describe the larger discovery cohort [24]
^aIn Dickson et al., the AD⁺LB⁺ individuals were subdivided into individuals with moderate or high AD pathology and brainstem, transitional, or diffuse LB pathology; the subgroup sizes are listed in the order moderate-brainstem, moderate-transitional, et cetera [18]. In Robinson et al., the AD⁺LB⁺ individuals were subdivided into individuals with primary intermediate or high AD pathology and secondary LB pathology and individuals with primary brainstem, limbic, or neocortical LB pathology [45]. In Kaivola et al., the AD⁺LB⁺ individuals were subdivided into individuals with intermediate or high AD pathology [27]. A separate analysis was performed on each subgroup in each of these three studies. ^bThese rows are populated only if an analysis was performed on an LB^– or LB⁺ group. In this case the sizes of the corresponding subgroups are marked as unknown (e.g., AD⁺LB⁺ and AD^–LB⁺ if LB⁺ is known). ^cThe six subgroups of this category were consolidated into two subgroups analyzed separately for association of APOE-ε4 with AD co-pathology versus sole intermediate or high AD pathology or LB co-pathology versus sole brainstem, limbic, or neocortical LB pathology: 130 individuals with primary AD pathology and secondary LB pathology and 96 with primary LB pathology and secondary AD pathology, respectively [45]

Back to article page

ISSN: 2051-5960

Contact us

Submission enquiries: JJM.Hoozemans@vumc.nl
General enquiries: info@biomedcentral.com